==== Front J Hematol Oncol J Hematol Oncol Journal of Hematology & Oncology 1756-8722 BioMed Central London 990 10.1186/s13045-020-00990-3 Review Targeting the Wnt/β-catenin signaling pathway in cancer Zhang Ya 123456 Wang Xin xinw007@126.comxinw@sdu.edu.cn 123456 1 grid.460018.b0000 0004 1769 9639Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021 Shandong China 2 Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250021 Shandong China 3 grid.27255.370000 0004 1761 1174School of medicine, Shandong University, Jinan, 250021 Shandong China 4 Shandong Provincial Engineering Research Center of Lymphoma, Jinan, 250021 Shandong China 5 Branch of National Clinical Research Center for Hematologic Diseases, Jinan, 250021 Shandong China 6 grid.429222.d0000 0004 1798 0228National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, 250021 China 4 12 2020 4 12 2020 2020 13 16523 9 2020 2 11 2020 © The Author(s) 2020Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.The aberrant Wnt/β-catenin signaling pathway facilitates cancer stem cell renewal, cell proliferation and differentiation, thus exerting crucial roles in tumorigenesis and therapy response. Accumulated investigations highlight the therapeutic potential of agents targeting Wnt/β-catenin signaling in cancer. Wnt ligand/ receptor interface, β-catenin destruction complex and TCF/β-catenin transcription complex are key components of the cascade and have been targeted with interventions in preclinical and clinical evaluations. This scoping review aims at outlining the latest progress on the current approaches and perspectives of Wnt/β-catenin signaling pathway targeted therapy in various cancer types. Better understanding of the updates on the inhibitors, antagonists and activators of Wnt/β-catenin pathway rationalizes innovative strategies for personalized cancer treatment. Further investigations are warranted to confirm precise and secure targeted agents and achieve optimal use with clinical benefits in malignant diseases. Keywords Wnt/β-catenin signaling pathwayCancerTargeted therapyCancer stem cellhttp://dx.doi.org/10.13039/501100001809National Natural Science Foundation of ChinaNo.82000195Zhang Ya National Natural Science FoundationNo. 81270598No. 81473486No. 81770210Wang Xin Key Research and Development Program of Shandong ProvinceNo.2018CXGC1213Wang Xin Technology Development Projects of Shandong ProvinceNo. 2017GSF18189Wang Xin Taishan Scholars Program of Shandong ProvinceNo.tsqn201909184Zhang Ya Academic promotion programme of Shandong First Medical University2020RC007Zhang Ya Shandong Provincial Hospital Youth Talent PlanShandong Provincial Hospital Research Incubation Fundissue-copyright-statement© The Author(s) 2020 ==== Body Introduction The Wnt/β-catenin signaling pathway, also called the canonical Wnt signaling pathway, is a conserved signaling axis participating in diverse physiological processes such as proliferation, differentiation, apoptosis, migration, invasion and tissue homeostasis [1–3]. Increasing evidence indicates that dysregulation of the Wnt/β-catenin cascade contributed to the development and progression of some solid tumors and hematological malignancies [4–8]. In the Wnt/β-catenin pathway, abnormal regulation of the transcription factor β-catenin, which is the pivotal component of the Wnt signaling pathway, leads to early events in carcinogenesis [9–12]. Within the degradation complex, glycogen synthase kinase 3β (GSK3β) and casein kinase 1α (CK1α) mediate the phosphorylation of β-catenin, promoting its ubiquitination and subsequent proteasomal degradation [13, 14]. The β-catenin-dependent signaling pathway is triggered by the binding of secreted cysteine-rich glycoprotein ligands Wnts to the LRP-5/6 receptors and FZD receptors. In the presence of Wnt ligand, the binding of Wnt ligand and receptors on the cell surface induces disheveled (DVL), causing the aggregation of the complex (AXIN, GSK3β, CK1, APC) to the receptor [15]. Subsequently, the phosphorylation and inhibition of GSK3β ensure an elevation of cytosolic β-catenin concentration. Un-phosphorylated β-catenin in the cytosol migrates to the nucleus and accumulates, interacting with T cell-specific factor (TCF)/lymphoid enhancer-binding factor (LEF) and co-activators, such as Pygopus and Bcl-9, to trigger the Wnt target genes like c-Myc, cyclin D1 and CDKN1A, resulting in the upregulation of TCF/LEF target gene. In addition, multiple regulatory mechanisms have been identified on the phosphorylation and ubiquitination of β-catenin by the degradation complex. Notum, which removes palmitoleate from Wnt proteins, blocks their extracellular secretion. Dickkopf (DKK) negatively regulates the initiation of Wnt protein-mediated signaling by competitively binding to LRP5/6 receptors. Besides, secreted FZD-related proteins (sFRPs), which bind to FZD receptors also blocking the initiation of Wnt protein-mediated signaling. Moreover, Wnt inhibitory factor (WIF) inhibits signaling by binding directly to Wnt proteins [16]. The transmembrane molecules ZNRF3 and RNF43 act on FZD molecules with E3 ubiquitin ligase activity [14, 17]. The 7-transmembrane receptor LGR4, LGR5 and LGR6 bind to R-spondins (RSPO) with high affinity to enhance the Wnt signal at a low dose of Wnt ligand [14, 18]. To elucidate the mechanism of Wnt/β-catenin signaling pathway activation and inhibition, a schematic diagram was depicted in Fig. 1.Fig. 1 Schematic representation of activated and inhibited Wnt/β-catenin pathway. “WNT ON state”: Upon ligation of Wnts to their receptors composed of frizzled proteins and LRP5/6, the cytoplasmic protein DVL is activated and induces the suppression of GSK3β. Subsequently, stabilized β-catenin translocates into the nucleus and binds to TCF/LEF transcription factors to lead to target gene transcription. “WNT OFF state”: In the absence of WNT ligand, the destruction complex of β-catenin, a tertiary complex formed by AXIN, CK1α, GSK3β and APC, phosphorylates β-catenin, which subsequently undergoes the ubiquitin-proteasomal degradation Furthermore, Wnt/β-catenin signaling orchestrates multiple cell signaling cascades, such as epidermal growth factor receptor (EGFR), Hippo/YAP, nuclear factor kappa-B (NF-κB), Notch, Sonic Hedgehog and PI3K/Akt pathway, which contribute to pivotal molecular mechanism in cancer development [19–24]. EGFR could form a complex with β-catenin and promotes the invasion and metastasis of cancer cells [25, 26]. Moreover, the Hippo pathway has been shown to inhibit Dvl phosphorylation, nuclear accumulation of β-catenin and transcription of β-catenin/TCF-target genes in the Wnt/β-catenin signaling [21, 27]. Besides, the activation of Wnt/β-catenin pathway interacted with PI3K/AKT/GSK-3 cascade in glioblastoma cells and further provided mechanistic basis for the chemoresistance to temozolomide [22]. Additionally, AKT kinase could also activate β-catenin. Therefore, the cross talk between Wnt/β-catenin and PI3K-AKT pathway was confirmed to promote tumorigenesis and resistance to cancer therapy [23, 28]. Collectively, underscoring the physiological importance of Wnt/β-catenin signaling pathway in tumorigenesis, targeted agents are explored and presented promising therapeutic potential in preclinical studies and clinical trials of some cancer types. In the present review, we elaborated on the advances and challenges of Wnt/β-catenin signaling pathway targeted interventions in malignancies, aiming to provide rationales and insights on novel strategies in cancer therapy. Wnt/β-catenin signaling pathway interventions for cancer The deregulation of Wnt/β-catenin signaling pathway is closely related to the initiation and progression of various types of cancers [4, 5, 29]. Thus, inhibitors, antagonists and agonists were designed to target this cascade in solid tumors (Table 1) and hematological malignancies (Table 2). Formulas and structures of agents targeted Wnt/β-catenin signaling pathway are listed in Additional file 1. Hallmarks of diverse categories of Wnt/β-catenin targeted agents in malignancies are illustrated in Fig. 2. In addition, Fig. 3 is plotted to present a panoramic overview of Wnt/β-catenin signaling pathway targeted interventions in cancer therapy, which was deciphered in the following aspects. Table 1 Clinical trials and preclinical evaluations on Wnt/β-catenin targeted agents in solid tumors Agents Mechanism Phase Cancer type Side effects Identifier WNT974 PORCN inhibitor Phase 2 Head and neck squamous cell cancer NR NCT02649530 WNT974 PORCN inhibitor Phase 1 Pancreatic cancer; colorectal cancer; melanoma; breast cancer; head and neck squamous cell cancer; cervical squamous cell cancer; esophageal squamous cell cancer; lung squamous cell cancer NR NCT01351103 *WNT974 (with LGX818 and Cetuximab) PORCN inhibitor Phase 1 Colorectal cancer NR NCT02278133 ETC-159 PORCN inhibitor Phase 1 Solid tumor Reversible hematological disorders NCT02521844 CGX1321 PORCN inhibitor Phase 1 Colorectal adenocarcinoma; gastric adenocarcinoma; pancreatic adenocarcinoma; bile duct carcinoma; hepatocellular carcinoma, esophageal carcinoma, Gastrointestinal cancer NR NCT03507998 *CGX1321 (with pembrolizumab) PORCN inhibitor Phase 1 Solid tumors; Gastrointestinal cancer NR NCT02675946 GNF-6231 PORCN inhibitor Preclinical Breast cancer NR – 90γ-OTSA-101 FZD10 antagonist Phase 1 Synovial sarcoma NR NCT01469975 OMP-18R5 Monoclonal antibody against FZD receptors Phase 1 Breast cancer Nausea, alopecia, fatigue, peripheral neuropathy NCT01973309 OMP-18R5 Monoclonal antibody against FZD receptors Phase 1 Solid tumors NR NCT01345201 *OMP-18R5 (with docetaxel) Monoclonal antibody against FZD receptors Phase 1 Solid tumors NR NCT01957007 *OMP-18R5 (with nab-paclitaxel and gemcitabine) Monoclonal antibody against FZD receptors Phase 1 Pancreatic cancer NR NCT02005315 OMP-54F28 FZD8 decoy receptor Phase 1 Solid tumors Dysgeusia, muscle spasms, hypophosphatemia NCT01608867 *OMP-54F28 (with sorafenib) FZD8 decoy receptor Phase 1 Hepatocellular cancer Diarrhea, neutropenia and decreased appetite NCT02069145 *OMP-54F28 (with paclitaxel and carboplatin) FZD8 decoy receptor Phase 1 Ovarian cancer NR NCT02092363 *OMP-54F28 (with nab-paclitaxel and gemcitabine) FZD8 decoy receptor Phase 1 Pancreatic cancer NR NCT02050178 Fz7-21 FZD7 antagonist Preclinical Gastroenteric tumor – – Salinomycin LRP5/6 inhibitor Preclinical Hepatocellular carcinoma; gastric cancer; colorectal cancer; bladder cancer; breast cancer – – FJ9 DVL inhibitor Preclinical Lung cancer; melanoma – – 3289–8625 DVL inhibitor Preclinical Ovarian cancer; lung cancer – – XAV939 Tankyrase inhibitor Preclinical Ovarian cancer; breast cancer – – JW74/ JW55 Tankyrase inhibitor Preclinical Osteosarcoma, colon carcinoma – – NVP-TNKS656 Tankyrase inhibitor Preclinical Hepatocellular carcinoma; colorectal cancer – – LZZ-02 Tankyrase inhibitor Preclinical Colonic carcinoma – – SSTC3 CK1α activator Preclinical Colorectal cancer – – LF3 β-catenin/TCF Preclinical Colon cancer – – KYA1797K/ KY1220 β-catenin Preclinical Colorectal cancer, breast cancer – – iCRT3/5 β-catenin/TCF Preclinical Breast cancer; gastric cancer – – ZINC02092166 β-catenin/TCF Preclinical Colorectal cancer – – NLS-StAx-h β-catenin/TCF Preclinical Colorectal cancer – – *PRI-724 (with leucovorin calcium, oxaliplatin, or fluorouracil) CBP/β-catenin antagonist Phase 2 Colorectal cancer Nausea, fatigue NCT02413853 PRI-724 CBP/β-catenin antagonist Phase 1 Pancreatic cancer NR NCT01764477 PRI-724 CBP/β-catenin antagonist Phase 1 Advanced solid tumors Nausea, vomiting, diarrhea, alopecia, fatigue, neutropenia, thrombocytopenia, neutropenic fever NCT01302405 ICG001 CBP antagonist Preclinical Pancreatic cancer, lung cancer, breast cancer; ovarian cancer – – Isoquercitrin CBP antagonist Preclinical Colorectal cancer – – Table 2 Clinical trials and preclinical evaluations on Wnt/β-catenin targeted agents in hematological malignancies Agents Mechanism Phase Cancer type Side effects Identifier CWP291 SAM68 inhibitor Phase 1 Relapsed or refractory AML and MDS Nausea, vomiting, diarrhea, and infusion-related reactions NCT01398462 PRI-724 CBP/β-catenin antagonist Phase 2 AML; CML NR NCT01606579 GNE-781 CBP antagonist Preclinical AML – – ICG001 CBP antagonist Preclinical AML; ALL; CML; MM – – WNT974 PORCN inhibitor Preclinical BL – Wnt-C59 PORCN inhibitor Preclinical cHL – IWP-2/IWP-4 PORCN inhibitor Preclinical AML; cHL – XAV939 Tankyrase inhibitor Preclinical AML; T-ALL; CML – IWR-1 Tankyrase inhibitor Preclinical APL – Salinomycin LRP5/6 inhibitor Preclinical CLL; MCL – iCRT14 β-catenin/TCF Preclinical ALL; MCL – Fig. 2 Hallmarks of diverse categories of Wnt/β-catenin targeted agents in cancer Fig. 3 Graphic overview of Wnt/β-catenin signaling pathway targeted interventions in cancer studies. Promising therapeutics targeting Wnt ligand/ receptor interface, β-catenin destruction complex and TCF/β-catenin transcription complex are investigated in preclinical and clinical evaluations Inhibitors targeting Wnt ligand/ receptor interface Porcupine inhibitors Porcupine (PORCN), a family member of membrane-bound O-acyltransferases (MBOAT), is key for the secretion of Wnt ligands [30, 31]. Several inhibitors that target PORCN prevent the palmitoylation of Wnt proteins in the endoplasmic reticulum, which subsequently prevents their secretion [13, 24]. Blocking the acylation of WNT with a PORCN inhibitor to abolish WNT secretion becomes an effective treatment strategy. WNT974 (LGK974) is an orally available small molecule inhibitor that decreases epithelial ovarian cancer (EOC) cell viability in vitro and inhibits tumor growth in vivo [24, 32]. In EOC preclinical mouse models, WNT974 presents enhanced anti-tumor effects with the combination of paclitaxel [33]. There is currently a phase I clinical trial investigating WNT974 monotherapy for patients with pancreatic cancer, triple-negative breast cancer and cervical squamous cell carcinoma (NCT01351103). CGX1321, another PORCN inhibitor, inhibits both canonical and non-canonical Wnt signaling pathways. The single-dose escalation of CGX1321 is invested in a phase 1 clinical trial (NCT02675946) in solid tumors. In an EOC mouse model, treatment with CGX1321 led to prolonged overall survival, decreased tumor burden and increased immune cell infiltration. Furthermore, effects of some other PORCN inhibitors were evaluated in preclinical studies [34, 35]. It was reported that the combination of the PORCN inhibitor ETC-159 and the PI3K inhibitor GDC-0941 decreased RNF43-mutant pancreatic cancer cell proliferation and xenograft growth in vivo [36]. Besides, IWP-O1 was observed with significantly improved metabolic stability and inhibit the phosphorylation of DVL in Hela cells [37]. Moreover, GNF-6231 demonstrated potent inhibition activities and induced robust anti-tumor efficacy in a breast cancer mouse model [38]. Wnt/FZD antagonists With the antagonism of Wnt ligands and FZD receptors, canonical Wnt signaling pathway was suppressed and indicated potential strategy in cancer therapy. Ipafricept (OMP54F28; IPA) is a recombinant fusion protein, including the cysteine-rich domain of FZD8 fused to a human IgG1 Fc fragment [39]. This structure could bind directly to Wnt ligands, competing for the binding of Wnt ligands with FZD8 receptor, thereby inhibiting Wnt regulated processes [40]. In patient-derived ovarian cancer xenograft mice models, ipafricept displayed activity to decrease the population of stem cells, suppress tumor development and promote differentiation. In addition, in preclinical studies, ipafricept exhibits synergistic anti-tumor effects combined with taxanes when given prior to chemotherapy two to three days, with 82% of the patients achieved a partial or complete response [41]. Ipafricept was also investigated in a phase 1b dose-escalation study in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. The combination of these three agents produced similar response rates and survival outcomes compared with historical treatment regimens. Nevertheless, bone toxicities at efficacy doses prevented further testing of this treatment regimen. A phase 1b clinical trials suggested that ipafricept could also be administered with nab-paclitaxel and gemcitabine with reasonable tolerance in patients with previously untreated stage IV pancreatic cancer [42]. OMP-18R5 (vantictumab) is a monoclonal antibody targeting FZD1, FZD2, FZD5, FZD7 and FZD8 [43–45]. OMP-18R5 blocks tumor growth in xenograft mouse models of breast, pancreatic, colon, lung, and head and neck cancers and is being evaluated in a number of phase I trials for these tumor types [43, 46]. In a clinical trial, OTSA-101 was demonstrated that radioimmunotherapy targeting FZD10 is feasible in synovial sarcoma patients [47]. Besides, Pavlovic et al. utilized combinatorial antibody engineering by phage display to generate a variant antibody F2.A with specificity of FZD4 [44]. F2.A suppresses pancreatic cancer tumor growth in xenograft mouse models. Interestingly, carbamazepine, an antiepileptic drug, was recently reported to bind the cysteine-rich domain of FZD8, which suggests been explored as a promising therapy option in cancers [48]. Additionally, Fz7-21, a selective FZD7-binding peptide, disrupts intestinal stem cells and organoids, implicating the potential of therapeutic application in malignant diseases [49]. LRP5/6 inhibitors As the co-receptor of Wnt, the phosphorylation of LRP5/6 promotes the activation of Wnt/β-catenin signaling pathway. The molecular complex Wnt-FZD-LRP5/6-DVL forms a structural region for AXIN interaction that disrupts degradation of β-catenin. BMD4503-2, a quinoxaline moiety, was identified as a new small-molecule inhibitor of the LRP5/6-sclerostin interaction through pharmacophore-based virtual screening and in vitro assays. The compound BMD4503-2 could revert the down-regulated activity of the Wnt/β-catenin signaling pathway through competitively binding to the LRP5/6-sclerostin complex [50]. DVL inhibitors DVL is important for Wnt signal transduction by recruiting components of the β-catenin destruction complex to the cell membrane [51, 52]. DVL binds to the cytoplasmic carboxyl terminal end of FZD proteins through its PDZ domain [53]. NSC668036, FJ9, and 3289–8625 are some agents that block the DVL-PDZ interaction, resulting in subsequently inhibition of the signal transduction pathway [54, 55]. The non-electrophilic indole-2-carbinol-based chemical scaffold of FJ9 disrupted the interaction between FZD and the PDZ domain of DVL. NSC668036 and 3289–8625 were confirmed to down-regulate Wnt/β-catenin signaling and inhibit tumor cell growth in lung, colorectal and cervical cancer cell lines in vitro, as well as in a lung cancer xenografts [54]. Agents targeting the β-catenin-destruction complex Tankyrase inhibitors Scaffolding protein AXIN is the rate-limiting component of the β-catenin destruction complex, which are constantly surveyed and regulated by tankyrases [56–58]. Tankyrases belong to the Poly (ADP-ribose) polymerases (PARPs) family, regulating the stability of AXIN1 and AXIN2 through directing AXIN ubiquitylation by RNF146 and proteasomal degradation [59, 60]. There are two isoforms, Tankyrase 1 (PARP5a) and Tankyrase 2 (PARP5b) involved in the Wnt/β-catenin signaling, increasing the degradation of AXIN by the ubiquitin–proteasome pathway [61–63]. Tankyrase inhibitor, XAV939 and IWR-1 regulated AXIN by inhibiting Tankyrase 1 and Tankyrase 2 [64, 65]. Treatment with XAV939 decreased the viability of EOC cell lines and increased radio-sensitivity in cervical cancer cells [66]. Furthermore, the tankyrase-specific inhibitor, JW74 and JW55 affects cell cycle progression and induced apoptosis and differentiation in osteosarcoma and colon carcinoma cells, respectively [67, 68]. In addition, mice xenografts and patient-derived sphere cultures of colorectal cancer (CRC) were incubated with a Tankyrase inhibitor NVP-TNKS656 combination with AKT and PI3K inhibitors. A decreased nuclear β-catenin level predicted for apoptosis suggesting the tankyrase inhibitor could overcome resistance to AKT and PI3K inhibitors [61]. The same antineoplastic effect was observed in LZZ-02, a novel Tankyrase 1/2 inhibitor [69]. Concerns of gastrointestinal toxicity have been noted in analysis of these inhibitors, and further studies are needed [70]. CK1 agonists Stabilizing the β-catenin destruction complex can block the nuclear localization of β-catenin, suggesting as an attractive therapeutic target. Feasible strategy for the repositioning of existing FDA approved drugs is explored for the treatment of malignancies with deregulated Wnt signaling. For example, pyrvinium, an existing FDA approved drug, can bind all CK1 family members in vitro, selectively potentiating CK1α kinase activity [71]. Colon cancer cells with APC mutations were sensitive to pyrvinium treatment with a decrease in both Wnt signaling and cell proliferation. Pyrvinium inhibits platinum-resistant tumor growth and induces apoptosis in vitro and in vivo, and these effects are enhanced when combined with paclitaxel. Pyrvinium blocks Wnt signal by decreasing β-catenin levels and suppressing the transcription of β-catenin targeted genes. However, cancer cells with increasing level of β-catenin are no longer impacted by pyrvinium [72, 73]. In addition, a novel small-molecule CK1α activator called SSTC3 has been proved to inhibit the growth of CRC xenografts in mice and also attenuate the growth of patient-derived metastatic CRC xenograft [74, 75]. Inhibitors targeting β-catenin/TCF transcription complex Several compounds targeting the downstream effectors, like transcription complex and co-activators, were identified by high through-put ELISA screening, such as PFK115-584 and CGP049090, which can block the β-catenin/TCF complex in a dose-dependent manner [76]. LF3, a 4-thioureido-benzenesulfonamide derivative, robustly disrupts the critical interaction between β-catenin and the transcription factor TCF4. Besides, LF3 reduced tumor growth and induced differentiation in a mouse xenograft model of colon cancer [77]. KYA1797K/ KY1220 effectively suppressed the growth of colorectal cancer and breast cancer cells via the destabilization of both β-catenin and Ras [78–80]. Mantle cell lymphoma-initiating cells were particularly sensitive to Wnt pathway inhibitors. Targeting β-catenin-TCF4 interaction with CCT036477, iCRT3, iCRT5, iCRT14 or PKF118-310 preferentially eliminated the survival of malignant cells of acute lymphoblastic leukemia, gastric cancer, and breast cancer [81–84]. ZINC02092166 suppresses canonical Wnt signaling, downregulates the expression of Wnt target genes and inhibits the growth of colorectal cancer cells [85]. Based on the acylhydrazone component, the inhibitory activities were evaluated in cellular assays. NLS-StAx-h, a selective cell-penetrating peptide inhibitor of β-catenin-transcription factor interactions suppressed proliferation and migration of colorectal cancer cells. CWP232291 (CWP291), another small molecule inhibited Wnt-mediated transcriptional activity, was under evaluation on phase 1 clinical trial in patients with relapsed or refractory AML and myelodysplastic syndrome (MDS) [86]. Active form of CWP232204 binds to Src-associated substrate in mitosis of 68 kDa (SAM68), which regulates alternative splicing TCF, and promotes β-catenin degradation via apoptosis. Further investigations will explore CWP291, with a mechanism of aiming at eradication of earlier progenitors via Wnt pathway blockade, as combination therapy. There are several co-activators of β-catenin-dependent transcription, including CREB binding protein (CBP). The CBPs are key transcriptional co-activators essential for a multitude of cellular processes and involved in human pathological conditions and cancer [87, 88]. Several CBP inhibitors have been developed in recent years and have shown promising antineoplastic effects in preclinical models with minimal off-target effects, such as PRI-724, ICG001, GNE-781, 1-(1H-indol-1-yl)ethenone, JW67, JW74, NLS-StAx-h, et al. [89–91]. PRI-724 is a first-in-class small molecule antagonist that inhibits the interaction between β-catenin and CBP [92]. It was phosphorylated-C-82 and was rapidly hydrolyzed to its active form C-82 in vivo [93]. In chemotherapy resistant EOC with hyperactivated CBP/β-catenin signaling, PRI-724 increased sensitization to platinum chemotherapy and preclinical studies had shown considerable toxicity profile [93, 94]. Monotherapy with ICG-001 led to the reduction of tumor-related characteristics [95, 96]. GNE-781 displayed anti-tumor activity in an acute myeloid leukemia (AML) model and was also shown to decrease Foxp3 transcript levels in a dose-dependent manner [90]. 1-(1H-indol-1-yl) ethenone markedly inhibited cell growth in several prostate cancer cell lines [89]. JW67 and JW74 were identified specifically inhibiting canonical Wnt pathway at the level of the destruction complex and inhibited the growth of colorectal cancer mouse xenograft model and multiple intestinal neoplasia mice [97]. Moreover, isoquercitrin showed anti-tumor effects on colon cancer cells (SW480, DLD-1 and HCT116), whereas exerting no significant effect on non-tumor colon cell (IEC-18), suggesting a specific effect in tumor cells in vitro [98]. Natural agents and new activity of old drugs It is notable that some of the natural agents exert anti-tumor activities via regulating canonical Wnt signaling pathway [99, 100]. Curcumin, isolated from the rhizome of Curcuma longa, modulates Wnt signaling pathway and exerts anti-tumor activities in melanoma, lung cancer, breast cancer, colon cancer, endothelial carcinoma, gastric carcinoma and hepatocellular carcinoma [101]. 3,3′-diindolylmethane (DIM), a natural compound derived from cruciferous vegetables inhibited proliferation of colon and colorectal cancer cells via Wnt/β-catenin pathway, highlighting as a promising chemo-preventive agent or chemo-radio-sensitizer for the prevention of tumor recurrence in cancer therapy [102]. Formononetin, isolated from the red clover, displayed anti-tumor activities in breast cancer and glioma cells with high-level IC50 values. To achieve high potency, formononetin was modified with a coumarin unit to design a derivate 10 via the molecular hybridization strategy. The analog 10 presented anti-proliferative effects through Wnt/β-catenin pathway in gastric cancer [103]. Besides, Wogonin, a major flavonoid compound isolated from Scutellaria radix, decreased intracellular levels of Wnt proteins and activated degradation β-catenin for proteasomal degradation [104]. Gigantol, a bibenzyl compound from orchid species, was also reported to inhibit Wnt/β-catenin signaling through down-regulation of phosphorylated LRP6 and cytosolic β-catenin in breast cancer cells [105]. Additionally, treatment of echinacoside, a phenylethanoid glycoside from Tibetan herbs, significantly reduced tumor growth and regulation of Wnt/β-catenin signaling [106]. Besides, nimbolide, a limonoid present in leaves of the neem tree, concurrently abrogated canonical Wnt signaling and induced intrinsic apoptosis in hepatocarcinoma cells [107]. Moreover, isoquercitrin, a natural flavonol compound, exerted an inhibitory effect on Wnt/β-catenin, where the flavonoid regulated downstream of β-catenin translocation to the nucleus [108]. It was also noted that triptonide, a diterpenoid epoxide presented in Tripterygium wilfordii, could effectively inhibit canonical Wnt/β-catenin signaling by targeting the downstream C-terminal transcription domain of β-catenin or a nuclear component associated with β-catenin and induced apoptosis of Wnt-dependent cancer cells [109]. Moreover, the fungus Exobasidium vexans and its subcomponent atranorin were reported to inhibit lung cancer cell motility and tumorigenesis by affecting nuclear import of β-catenin and downregulating β-catenin/LEF downstream target genes [110]. In addition, researchers had found some old drugs performed new tricks, which play important roles in tumor growth, invasion and metastasis via regulating Wnt/β-catenin signaling pathway. Carbamazepine, an antiepileptic drug, was recently reported to bind the cysteine-rich domain of FZD8, which suggested to been explored as a promising therapy option in cancers [48]. It was also reported that psychiatric agent hexachlorophene attenuated Wnt/β-catenin signaling through suppressing β-catenin degradation in colon cancer cells [111]. Salinomycin, a type of antibiotics, was reported to trigger ionic changes to inhibit proximal Wnt signaling by interfering with LPR6 phosphorylation, and thus impairing the survival of cells that depend on Wnt signaling at the plasma membrane [112–116]. Besides, hematein was found to inhibit cancer cell growth and increased apoptosis through Wnt/TCF pathway [117]. Trifluoperazine (TFP), used as an antipsychotic and antiemetics, had been found to inhibit lung CSC spheroid formation ability and suppress expression of lung CSC markers (e.g., CD44/CD133) by inhibiting Wnt/β-catenin signal transduction [118]. The similar activities were also investigated in thioridazine, pimozide and diphenylbutylpiperidine class, other antiangiogenic agents [119–121]. It is notable that cyclooxygenases (COX1 and 2) inhibitors (e.g., aspirin, celecoxib, sulindac and ursolic acid) could inhibit Wnt/β-catenin pathway in cancer cells [122–124]. Aspirin increased expression of the Wnt antagonist Dickkopf-1, which suppressed activities of cancer stem cells in CRC cells [125]. Cancer stem cells -Wnt/β-catenin signaling pathway inhibitors CSCs display many characteristics of embryonic or tissue stem cells and often show continuous activation of highly conserved signaling pathways related to development and tissue homeostasis [126, 127]. The Wnt/β-catenin signaling pathway is associated with regulating the pluripotency, self-renewal of stem cells and differentiation ability [1, 128]. Abnormal activation of the Wnt/β-catenin pathway promotes CSC progression and thus leads to the deterioration and metastasis of cancer [129]. For instance, abnormal activation of Wnt signaling disrupted the normal growth and differentiation of colonic crypt stem cells, resulting in a colorectal CSC phenotype by upregulating expression of target genes such as c-MYC and cyclin D [130]. Moreover, one study showed that experimental knockdown of CD146 could dedifferentiate colorectal cancer cells to acquire a stem cell phenotype through inhibiting GSK-3β which in turn promoted nuclear translocation of β-catenin for Wnt signaling activation [131]. Recent studies identified SAM68 as a novel transcriptional modulator selectively targeting CSCs over healthy stem cells via Wnt/β-catenin signaling [132]. Wnt/β-catenin signaling also exerts a crucial role in early hematopoiesis, notably in hematopoietic stem cells (HSCs). Loss- and gain-of-function studies demonstrated that Wnt signaling and β-catenin activity were necessary for proper function and cellularity control of hematopoietic cells including HSCs and MKs12-15 [133]. Overactive Wnt/β-catenin signaling led to exhaustion of HSCs, causing multilineage differentiation block and compromised hematopoietic stem cell maintenance [134]. Several compounds have been identified to target CSCs via Wnt/β-catenin signaling pathway (Table 3, Fig. 4). It has been reported that PORCN inhibitor WNT974 (LGK-974) inhibited the proliferation of breast CSCs [135, 136]. Niclosamide, an FDA approved anti-helminthic agent was identified as an inhibitor of the Wnt/β-catenin pathway and showed anti-tumor properties to selectively target ovarian CSCs [137]. In addition, niclosamide decreased the level of CSCs by reducing the expression of LRP6 and β-catenin in basal-like breast cancer [138, 139]. Notably, in a phase 2 trial, the safety and effectiveness of niclosamide was proved in the treatment of colorectal cancer [140]. Furthermore, niclosamide can reduce the expression of many components in the Wnt/β-catenin signaling pathway, the self-renewal ability and population of CSCs in CRC [141]. Additionally, ONC201, which is in a phase I/II study for patients with advanced cancer (NCT02038699), induced significant CSC-suppression and repress the expression of CSC-related genes in prostate and glioblastoma tumors through suppressing the Wnt signaling pathway [142–144].Table 3 Small-molecule compounds targeting Wnt/β-catenin cascade to inhibit cancer stem cells Agents Target Phase Type of cancer Side effects References WNT974 PORCN inhibitor Phase I Breast cancer Not reported Solzak JP et al. [136] Niclosamide Wnt/β-catenin Phase II Colorectal cancer Vomiting, diarrhea, and colitis Burock S et al. [140] Wnt/β-catenin Preclinical Ovarian cancer Not reported Lin CK et al. [137] LRP6, β-catenin Preclinical Basal-like breast cancer Not reported Ye T et al. [139] ONC201 Wnt/β-catenin Phase I/ II Glioblastoma cancer Not reported Arrillaga-Romany I et al. [144] Preclinical Prostate cancer Not reported Lev A et al. [143] XAV939 Tankyrase inhibitor Preclinical Colon cancer Not reported Wu X et al. [147] Preclinical Head and neck squamous cell carcinoma Not reported Roy S et al. [146] IWR-1 Tankyrase inhibitor Preclinical Osteosarcoma Not reported Martins-Neves SR et al. [148] TFP Wnt/β-catenin Preclinical Lung cancer Not reported Yeh CT et al. [118] AD and Ts Wnt/β-catenin Preclinical Lung cancer Not reported Lamture G et al. [165] Chelerythrine β-catenin Preclinical Non-small cell lung carcinoma Not reported Medvetz D et al. [150] Wnt-C59 PORCN inhibitor Preclinical Nasopharyngeal carcinoma Not reported Cheng Y et al. [152] IC-2 Wnt Preclinical Hepatocellular carcinoma Not reported Seto K et al Preclinical Colorectal cancer Not reported Urushibara S et al JIB-04 β-catenin Preclinical Colorectal cancer Not reported Kim M et al. [153] FH535 Wnt/β-catenin Preclinical Pancreatic cancer Not reported Razak S et al. [155] Docetaxel and sulforaphane β-catenin Preclinical Breast cancer Not reported de Bessa Garcia SA et al. [157] Pyrvinium pamoate β-catenin Preclinical Breast cancer Not reported Xu L et al. [158] SKL2001 Axin/β-catenin Preclinical Mesenchymal stem cell Not reported Jiwon Choi et al. [159] Fig. 4 The schematic model of abnormal activation of the Wnt/β-catenin pathway promoting cancer stem cell progression and thus leading to the deterioration and metastasis of cancer Furthermore, many potential compounds targeting CSCs through inhibiting Wnt/β-catenin signaling pathway have been undertaken in preclinical evaluations. For example, XAV939 inhibited β-catenin signaling, thus attenuated CSC progression, thereby eliminating the CSC-mediated chemical resistance in head and neck squamous cell carcinoma (HNSCC) and colon cancer cells [145–147]. IWR-1, a tankyrase inhibitor, can hamper the expression of key stem markers in osteosarcoma, impair osteosarcoma CSC self-renewal and enhance doxorubicin sensitivity by affecting β-catenin translocation in vivo [148]. Trifluoperazine (TFP), used as an antipsychotic and antiemetics, has been found to inhibit lung CSC spheroid formation ability and suppress expression of lung CSC markers (e.g., CD44/ CD133) by inhibiting Wnt/β-catenin signal transduction [118]. Additionally, actinomycin D (AD) and telmisartan (TS) can also attenuate the number and activity of CSC and reduce CSC marker expression (such as ALDH1, SOX2 and NOS2) in lung cancer by blocking the Wnt/β-catenin signaling pathway. Besides, chelerythrine was identified to down-regulate the level of β-catenin and inhibited CSC invasion, spheroid formation and the expression of the stem marker SOX2 in non-small cell lung carcinoma (NSCLC) [149, 150]. Wnt-C59 (C59), an inhibitor of Wnt, decreased the sphere formation ability of CSCs dose-dependently in nasopharyngeal carcinoma (NPC) [151]. IC-2, a novel small-molecule Wnt inhibitor, reduced the population of CD44+ cells (liver CSCs) and the sphere-forming ability of hepatocellular carcinoma (HCC) cells, as well as in CRC and bladder cancer cells [152]. In addition, IC-2 increased the sensitivity of 5-FU in the DLD-1 cells, a CRC cell line. Moreover, JIB-04, a selective inhibitor of histone demethylase, significantly attenuated CSC tumor sphere formation, migration and invasion in vitro by regulating the recruitment of β-catenin [153]. A similar phenomenon was noted in FH535, which could suppress the expression of the liver CSC marker CD24 and CD44 [154, 155]. The combination of docetaxel (DTX) and sulforaphane (SFN) and pyrvinium pamoate (PP) can both inhibit the EMT (epithelial–mesenchymal transition), CSC self-renewal ability and drug resistance by decreasing β-catenin expression in BCSCs [156–158]. Additionally, SKL2001, an agonist of the Wnt/β-catenin pathway, stabilizes intracellular β-catenin via disruption of the AXIN/β-catenin interaction [159]. The treatment of mesenchymal stem cells with SKL2001 promoted osteoblastogenesis and suppressed adipocyte differentiation, providing a new strategy to regulate mesenchymal stem cell differentiation by modulation of the Wnt/β-catenin pathway. Besides, 5-FU was reported to promote stemness of colorectal cancer via p53-mediated WNT/β-catenin pathway activation [160]. Anti-progastrin humanized antibodies were investigated to decrease self-renewal of CSCs via Wnt signaling and represent potential novel strategies for K-RAS-mutated colorectal cancer [161]. Challenges of Wnt/β-catenin signaling targeted agents in cancer Aberrant activation of Wnt/β-catenin signaling drives oncogenic transformation in a wide range of cancers, indicating the key pathway modulators as attractive therapeutic targets in malignancies. Despite that Wnt/β-catenin targeted therapies are varied and clinical experience nascent, with the development of the targeted agents and combination strategies under investigation, the risk for off-targeting effectivity, side effects and toxicities are not allowed to be neglected. Of note, the critical role of Wnt/β-catenin signaling in stem cell maintenance raised concerns regarding the dose-limiting toxicity of targeted agents in bone, hair and gastrointestinal tract as well as in hematopoiesis, which limited of its clinical application [162–164]. Besides, considerable cross talks between the Wnt/β-catenin signaling pathway with other pathways are critical to designing effective therapeutic approaches. The combination therapy with agents that have impacts on multiple pathways in solid and hematologic malignancies needs long-term follow-up observation. Therefore, further exploration and evaluation are warranted to identify precise and safe targeted agents and achieve optimal use with clinical benefits in cancer. Conclusions Novel strategies are imperative to improve the outcome of cancer patients. With great advances in the knowledge of molecular basis and the constant effort for improvement, preclinical investigations and clinical trials have been conducted on the Wnt/β-catenin signaling targeted interventions in malignancies. The Wnt/β-catenin signaling targeted regimens have been proved to represent promising candidates of individualized approaches in the treatment of cancer patients. Further investigations are expected on confirming the safety, efficacy, patient stratification and drug delivery of innovative Wnt/β-catenin targeted therapies in cancer. Supplementary information Additional file 1. Formulas and structures of agents targeted Wnt/β-catenin signaling pathway. Abbreviations PORCNPorcupine CBPCREB binding protein DVLDisheveled EOCEpithelial ovarian cancer CRCColorectal cancer CSCCancer stem cells FZDFrizzled LRPLow density lipoprotein receptor-related protein TCF/LEFTranscription factor/ Lymphoid Enhancer Binding Factor AXINAnti-Neurexin GSK3βGlycogen synthase kinase-3β APCAdenomatous polyposis coli gene LGRLeucine-rich repeat containing G protein-coupled receptors RSPOR-spondin AMLAcute myeloid leukemia APLAcute promyelocytic leukemia ALLAcute lymphocytic leukemia CMLChronic myeloid leukemia CLLChronic lymphocytic leukemia MDSMyelodysplastic Syndromes BLBurkitt’s lymphoma HLHodgkin lymphoma MCLMantle cell lymphoma Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Supplementary information Supplementary information accompanies this paper at 10.1186/s13045-020-00990-3. Not applicable. Authors’ contributions Y.Z. drafted the manuscript. X.W. and Y.Z. revised the manuscript. Both authors reviewed and approved the final manuscript. Funding This study was funded by Translational Research Grant of National Clinical Research Center for Hematologic Diseases (NCRCH) (No.2020ZKMB01); National Natural Science Foundation (Nos. 82000195, 82070203,  81770210, 81473486 and 81270598); Key Research and Development Program of Shandong Province (No. 2018CXGC1213); Technology Development Projects of Shandong Province (No. 2017GSF18189); Taishan Scholars Program of Shandong Province; Shandong Provincial Natural Science Foundation (No.ZR201911140028); Shandong Provincial Engineering Research Center of Lymphoma; Academic Promotion Programme of Shandong First Medical University; Shandong Provincial Hospital Youth Talent Plan; Shandong Provincial Hospital Research Incubation Fund. Availability of data and materials Not applicable. Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. ==== Refs References 1. Salik B, Yi H, Hassan N, Santiappillai N, Vick B, Connerty P, Duly A, Trahair T, Woo A, Beck D et al: Targeting RSPO3-LGR4 signaling for leukemia stem cell eradication in acute myeloid leukemia. Cancer Cell 2020. 2. Soleas J D'Arcangelo E Huang L Karoubi G Nostro M McGuigan A Waddell T Assembly of lung progenitors into developmentally-inspired geometry drives differentiation via cellular tension Biomaterials 2020 254 120128 10.1016/j.biomaterials.2020.120128 32474250 3. Choi B Cave C Na C Sockanathan S GDE2-dependent activation of canonical wnt signaling in neurons regulates oligodendrocyte maturation Cell Rep 2020 31 5 107540 10.1016/j.celrep.2020.107540 32375055 4. Zhang M Weng W Zhang Q Wu Y Ni S Tan C Xu M Sun H Liu C Wei P The lncRNA NEAT1 activates Wnt/β-catenin signaling and promotes colorectal cancer progression via interacting with DDX5 J Hematol Oncol 2018 11 1 113 10.1186/s13045-018-0656-7 30185232 5. Cao M-Q You AB Zhu X-D Zhang W Zhang Y-Y Zhang S-Z Zhang K-W Cai H Shi W-K Li X-L miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a J Hematol Oncol 2018 11 1 12 10.1186/s13045-018-0555-y 29361949 6. Ge X Wang X Role of Wnt canonical pathway in hematological malignancies Journal of hematology & oncology 2010 3 33 10.1186/1756-8722-3-33 20843302 7. He S Tang S WNT/β-catenin signaling in the development of liver cancers Biomed Pharmacother 2020 132 110851 10.1016/j.biopha.2020.110851 33080466 8. Gajos-Michniewicz A, Czyz M: WNT Signaling in melanoma. Int J Mol Sci 2020, 21(14). 9. Zhang X, Wang L, Qu Y. Targeting the β-catenin signaling for cancer therapy. Pharmacol Res 2020:104794 10. Wei C Zhu M Yang Y Zhang P Yang X Peng R Gao C Lu J Wang L Deng X Downregulation of RNF128 activates Wnt/β-catenin signaling to induce cellular EMT and stemness via CD44 and CTTN ubiquitination in melanoma J Hematol Oncol 2019 12 1 21 10.1186/s13045-019-0711-z 30832692 11. Zhou J Toh SHM Chan Z-L Quah JY Chooi J-Y Tan TZ Chong PSY Zeng Q Chng W-J A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase J Hematol Oncol 2018 11 1 36 10.1186/s13045-018-0581-9 29514683 12. Lim Z-F Ma PC Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy J Hematol Oncol 2019 12 1 134 10.1186/s13045-019-0818-2 31815659 13. Wiese KE, Nusse R, van Amerongen R: Wnt signalling: conquering complexity. Development 2018, 145(12). 14. Nusse R Clevers H Wnt/beta-catenin signaling, disease, and emerging therapeutic modalities Cell 2017 169 6 985 999 10.1016/j.cell.2017.05.016 28575679 15. Bilic J Huang YL Davidson G Zimmermann T Cruciat CM Bienz M Niehrs C Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation Science 2007 316 5831 1619 1622 10.1126/science.1137065 17569865 16. Jaschke N Hofbauer LC Gobel A Rachner TD Evolving functions of Dickkopf-1 in cancer and immunity Cancer Lett 2020 482 1 7 10.1016/j.canlet.2020.03.031 32251706 17. Ci Y Li X Chen M Zhong J North B Inuzuka H He X Li Y Guo J Dai X SCF E3 ubiquitin ligase targets the tumor suppressor ZNRF3 for ubiquitination and degradation Protein Cell 2018 9 10 879 889 10.1007/s13238-018-0510-2 29497989 18. Zebisch M Xu Y Krastev C MacDonald B Chen M Gilbert R He X Jones E Structural and molecular basis of ZNRF3/RNF43 transmembrane ubiquitin ligase inhibition by the Wnt agonist R-spondin Nat Commun 2013 4 2787 10.1038/ncomms3787 24225776 19. Hu T Li C Convergence between Wnt-β-catenin and EGFR signaling in cancer Mol Cancer 2010 9 236 10.1186/1476-4598-9-236 20828404 20. Chen L Qin F Deng X Avruch J Zhou D Hippo pathway in intestinal homeostasis and tumorigenesis Protein Cell 2012 3 4 305 310 10.1007/s13238-012-2913-9 22492181 21. Liu T, Wei Q, Jin J, Luo Q, Liu Y, Yang Y, Cheng C, Li L, Pi J, Si Y et al: The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Nucleic Acids Res 2020. 22. Tomar VS Patil V Somasundaram K Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy Cell Biol Toxicol 2020 36 3 273 278 10.1007/s10565-019-09502-7 31758290 23. Perry JM Tao F Roy A Lin T He XC Chen S Lu X Nemechek J Ruan L Yu X Overcoming Wnt-β-catenin dependent anticancer therapy resistance in leukaemia stem cells Nat Cell Biol 2020 22 6 689 700 10.1038/s41556-020-0507-y 32313104 24. Krishnamurthy N Kurzrock R Targeting the Wnt/beta-catenin pathway in cancer: update on effectors and inhibitors Cancer Treat Rev 2018 62 50 60 10.1016/j.ctrv.2017.11.002 29169144 25. Suzuki M Shigematsu H Nakajima T Kubo R Motohashi S Sekine Y Shibuya K Iizasa T Hiroshima K Nakatani Y Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer Clin Cancer Res 2007 13 20 6087 6092 10.1158/1078-0432.CCR-07-0591 17947472 26. Joosten SPJ Spaargaren M Clevers H Pals ST Hepatocyte growth factor/MET and CD44 in colorectal cancer: partners in tumorigenesis and therapy resistance Biochim Biophys Acta Rev Cancer 2020 1874 2 188437 10.1016/j.bbcan.2020.188437 32976979 27. Imajo M Miyatake K Iimura A Miyamoto A Nishida E A molecular mechanism that links Hippo signalling to the inhibition of Wnt/β-catenin signalling EMBO J 2012 31 5 1109 1122 10.1038/emboj.2011.487 22234184 28. Toh TB Lim JJ Hooi L Rashid MBMA Chow EK-H: Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma J Hepatol 2020 72 1 104 118 10.1016/j.jhep.2019.08.035 31541681 29. Spaan I Raymakers RA van de Stolpe A Peperzak V Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential J Hematol Oncol 2018 11 1 67 10.1186/s13045-018-0615-3 29776381 30. Torres V Godoy J Inestrosa N Modulating Wnt signaling at the root: porcupine and Wnt acylation Pharmacol Ther 2019 198 34 45 10.1016/j.pharmthera.2019.02.009 30790642 31. Kabiri Z Numata A Kawasaki A Edison, Tenen D, Virshup D: Wnts are dispensable for differentiation and self-renewal of adult murine hematopoietic stem cells Blood 2015 126 9 1086 1094 10.1182/blood-2014-09-598540 26089398 32. Agarwal P Zhang B Ho Y Cook A Li L Mikhail F Wang Y McLaughlin M Bhatia R Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI Blood 2017 129 8 1008 1020 10.1182/blood-2016-05-714089 28011678 33. Doo DW Meza-Perez S Londono AI Goldsberry WN Katre AA Boone JD Moore DJ Hudson CT Betella I McCaw TR Inhibition of the Wnt/beta-catenin pathway enhances antitumor immunity in ovarian cancer Ther Adv Med Oncol 2020 12 1758835920913798 10.1177/1758835920913798 32313567 34. Madan B Ke Z Harmston N Ho SY Frois AO Alam J Jeyaraj DA Pendharkar V Ghosh K Virshup IH Wnt addiction of genetically defined cancers reversed by PORCN inhibition Oncogene 2016 35 17 2197 2207 10.1038/onc.2015.280 26257057 35. García-Reyes B Witt L Jansen B Karasu E Gehring T Leban J Henne-Bruns D Pichlo C Brunstein E Baumann U Discovery of inhibitor of wnt production 2 (IWP-2) and related compounds as selective ATP-competitive inhibitors of casein Kinase 1 (CK1) δ/ε J Med Chem 2018 61 9 4087 4102 10.1021/acs.jmedchem.8b00095 29630366 36. Zhong Z Sepramaniam S Chew XH Wood K Lee MA Madan B Virshup DM PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers Oncogene 2019 38 40 6662 6677 10.1038/s41388-019-0908-1 31391551 37. You L Zhang C Yarravarapu N Morlock L Wang X Zhang L Williams NS Lum L Chen C Development of a triazole class of highly potent Porcn inhibitors Bioorg Med Chem Lett 2016 26 24 5891 5895 10.1016/j.bmcl.2016.11.012 27876319 38. Cheng D Liu J Han D Zhang G Gao W Hsieh MH Ng N Kasibhatla S Tompkins C Li J Discovery of pyridinyl acetamide derivatives as potent, selective, and orally bioavailable porcupine inhibitors ACS Med Chem Lett 2016 7 7 676 680 10.1021/acsmedchemlett.6b00038 27437076 39. Le PN McDermott JD Jimeno A Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28 Pharmacol Ther 2015 146 1 11 10.1016/j.pharmthera.2014.08.005 25172549 40. Moore KN Gunderson CC Sabbatini P McMeekin DS Mantia-Smaldone G Burger RA Morgan MA Kapoun AM Brachmann RK Stagg R A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer Gynecol Oncol 2019 154 2 294 301 10.1016/j.ygyno.2019.04.001 31174889 41. Fischer MM Cancilla B Yeung VP Cattaruzza F Chartier C Murriel CL Cain J Tam R Cheng CY Evans JW WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death Sci Adv 2017 3 6 e1700090 10.1126/sciadv.1700090 28691093 42. Dotan E, Cardin DB, Lenz H-J, Messersmith W, O'Neil B, Cohen SJ, Denlinger CS, Shahda S, Astsaturov I, Kapoun AM et al: Phase Ib study of Wnt inhibitor ipafricept with gemcitabine and nab-paclitaxel in patients with previously untreated stage IV pancreatic cancer. Clin Cancer Res 2020. 43. Gurney A Axelrod F Bond CJ Cain J Chartier C Donigan L Fischer M Chaudhari A Ji M Kapoun AM Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors Proc Natl Acad Sci U S A 2012 109 29 11717 11722 10.1073/pnas.1120068109 22753465 44. Pavlovic Z Adams JJ Blazer LL Gakhal AK Jarvik N Steinhart Z Robitaille M Mascall K Pan J Angers S A synthetic anti-Frizzled antibody engineered for broadened specificity exhibits enhanced anti-tumor properties MAbs 2018 10 8 1157 1167 10.1080/19420862.2018.1515565 30183492 45. Flanagan D Barker N Costanzo N Mason E Gurney A Meniel V Koushyar S Austin C Ernst M Pearson H Frizzled-7 is required for wnt signaling in gastric tumors with and without mutations Can Res 2019 79 5 970 981 10.1158/0008-5472.CAN-18-2095 46. Le PN Keysar SB Miller B Eagles JR Chimed TS Reisinger J Gomez KE Nieto C Jackson BC Somerset HL Wnt signaling dynamics in head and neck squamous cell cancer tumor-stroma interactions Mol Carcinog 2019 58 3 398 410 10.1002/mc.22937 30378175 47. Giraudet A-L Cassier PA Iwao-Fukukawa C Garin G Badel J-N Kryza D Chabaud S Gilles-Afchain L Clapisson G Desuzinges C A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients BMC Cancer 2018 18 1 646 10.1186/s12885-018-4544-x 29884132 48. Zhao Y Ren J Hillier J Lu W Jones EY Antiepileptic drug carbamazepine binds to a novel pocket on the wnt receptor frizzled-8 J Med Chem 2020 63 6 3252 3260 10.1021/acs.jmedchem.9b02020 32049522 49. Nile AH de Sousa EMF Mukund S Piskol R Hansen S Zhou L Zhang Y Fu Y Gogol EB Komuves LG A selective peptide inhibitor of Frizzled 7 receptors disrupts intestinal stem cells Nat Chem Biol 2018 14 6 582 590 10.1038/s41589-018-0035-2 29632413 50. Choi J Lee K Kang M Lim S-K Tai No K In silico discovery of quinoxaline derivatives as novel LRP5/6-sclerostin interaction inhibitors Bioorg Med Chem Lett 2018 28 6 1116 1121 10.1016/j.bmcl.2018.01.050 29486968 51. Zhang X Zhu J Yang GY Wang QJ Qian L Chen YM Chen F Tao Y Hu HS Wang T Dishevelled promotes axon differentiation by regulating atypical protein kinase C Nat Cell Biol 2007 9 7 743 754 10.1038/ncb1603 17558396 52. Jiang X Charlat O Zamponi R Yang Y Cong F Dishevelled promotes Wnt receptor degradation through recruitment of ZNRF3/RNF43 E3 ubiquitin ligases Mol Cell 2015 58 3 522 533 10.1016/j.molcel.2015.03.015 25891077 53. Wong HC Bourdelas A Krauss A Lee HJ Shao Y Wu D Mlodzik M Shi DL Zheng J Direct binding of the PDZ domain of Dishevelled to a conserved internal sequence in the C-terminal region of Frizzled Mol Cell 2003 12 5 1251 1260 10.1016/S1097-2765(03)00427-1 14636582 54. Fujii N You L Xu Z Uematsu K Shan J He B Mikami I Edmondson LR Neale G Zheng J An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth Cancer Res 2007 67 2 573 579 10.1158/0008-5472.CAN-06-2726 17234765 55. Grandy D Shan J Zhang X Rao S Akunuru S Li H Zhang Y Alpatov I Zhang XA Lang RA Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled J Biol Chem 2009 284 24 16256 16263 10.1074/jbc.M109.009647 19383605 56. Lee E Salic A Krüger R Heinrich R Kirschner MW The roles of APC and Axin derived from experimental and theoretical analysis of the Wnt pathway PLoS Biol 2003 1 1 E10 10.1371/journal.pbio.0000010 14551908 57. Bernkopf D Brückner M Hadjihannas M Behrens J An aggregon in conductin/axin2 regulates Wnt/β-catenin signaling and holds potential for cancer therapy Nat Commun 2019 10 1 4251 10.1038/s41467-019-12203-8 31534175 58. Ji L Lu B Zamponi R Charlat O Aversa R Yang Z Sigoillot F Zhu X Hu T Reece-Hoyes J USP7 inhibits Wnt/β-catenin signaling through promoting stabilization of Axin Nat Commun 2019 10 1 4184 10.1038/s41467-019-12143-3 31519875 59. Xu D Liu J Fu T Shan B Qian L Pan L Yuan J USP25 regulates Wnt signaling by controlling the stability of tankyrases Genes Dev 2017 31 10 1024 1035 10.1101/gad.300889.117 28619731 60. Masuda M Sawa M Yamada T Therapeutic targets in the Wnt signaling pathway: feasibility of targeting TNIK in colorectal cancer Pharmacol Ther 2015 156 1 9 10.1016/j.pharmthera.2015.10.009 26542362 61. Arques O Chicote I Puig I Tenbaum SP Argiles G Dienstmann R Fernandez N Caratu G Matito J Silberschmidt D Tankyrase inhibition blocks Wnt/beta-catenin pathway and reverts resistance to PI3K and AKT inhibitors in the treatment of colorectal cancer Clin Cancer Res 2016 22 3 644 656 10.1158/1078-0432.CCR-14-3081 26224873 62. Schatoff E Goswami S Zafra M Foronda M Shusterman M Leach B Katti A Diaz B Dow L Distinct colorectal cancer-associated APC mutations dictate response to tankyrase inhibition Cancer Discov 2019 9 10 1358 1371 10.1158/2159-8290.CD-19-0289 31337618 63. Distler A Deloch L Huang J Dees C Lin N Palumbo-Zerr K Beyer C Weidemann A Distler O Schett G Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling Ann Rheum Dis 2013 72 9 1575 1580 10.1136/annrheumdis-2012-202275 23148305 64. Tian XH Hou WJ Fang Y Fan J Tong H Bai SL Chen Q Xu H Li Y XAV939, a tankyrase 1 inhibitior, promotes cell apoptosis in neuroblastoma cell lines by inhibiting Wnt/beta-catenin signaling pathway J Exp Clin Cancer Res 2013 32 100 10.1186/1756-9966-32-100 24308762 65. Riffell JL Lord CJ Ashworth A Tankyrase-targeted therapeutics: expanding opportunities in the PARP family Nat Rev Drug Discov 2012 11 12 923 936 10.1038/nrd3868 23197039 66. Zhang J Si J Gan L Guo M Yan J Chen Y Wang F Xie Y Wang Y Zhang H Inhibition of Wnt signalling pathway by XAV939 enhances radiosensitivity in human cervical cancer HeLa cells Artif Cells Nanomed Biotechnol 2020 48 1 479 487 10.1080/21691401.2020.1716779 31975621 67. Stratford EW Daffinrud J Munthe E Castro R Waaler J Krauss S Myklebost O The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines Cancer Med 2014 3 1 36 46 10.1002/cam4.170 24403055 68. Waaler J Machon O Tumova L Dinh H Korinek V Wilson SR Paulsen JE Pedersen NM Eide TJ Machonova O A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice Can Res 2012 72 11 2822 2832 10.1158/0008-5472.CAN-11-3336 69. Li B, Liang J, Lu F, Zeng G, Zhang J, Ma Y, Liu P, Wang Q, Zhou Q, Chen L: Discovery of novel inhibitor for WNT/β-catenin pathway by tankyrase 1/2 structure-based virtual screening. Molecules 2020, 25(7). 70. Zhong Y Katavolos P Nguyen T Lau T Boggs J Sambrone A Kan D Merchant M Harstad E Diaz D Tankyrase inhibition causes reversible intestinal toxicity in mice with a therapeutic index < 1 Toxicol Pathol 2016 44 2 267 278 10.1177/0192623315621192 26692561 71. Thorne CA Hanson AJ Schneider J Tahinci E Orton D Cselenyi CS Jernigan KK Meyers KC Hang BI Waterson AG Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha Nat Chem Biol 2010 6 11 829 836 10.1038/nchembio.453 20890287 72. Zhang C Zhang Z Zhang S Wang W Hu P Targeting of Wnt/beta-catenin by anthelmintic drug pyrvinium enhances sensitivity of ovarian cancer cells to chemotherapy Med Sci Monit 2017 23 266 275 10.12659/MSM.901667 28090074 73. Wei W, Liu H, Yuan J, Yao Y: Targeting Wnt/beta-catenin by anthelmintic drug niclosamide overcomes paclitaxel resistance in esophageal cancer. Fundam Clin Pharmacol 2020. 74. Li B, Orton D, Neitzel LR, Astudillo L, Shen C, Long J, Chen X, Kirkbride KC, Doundoulakis T, Guerra ML et al: Differential abundance of CK1α provides selectivity for pharmacological CK1α activators to target WNT-dependent tumors. Sci Signal 2017, 10(485). 75. Rodriguez-Blanco J Li B Long J Shen C Yang F Orton D Collins S Kasahara N Ayad NG McCrea HJ A CK1α activator penetrates the brain and shows efficacy against drug-resistant metastatic medulloblastoma Clin Cancer Res 2019 25 4 1379 1388 10.1158/1078-0432.CCR-18-1319 30487124 76. Lepourcelet M Chen YN France DS Wang H Crews P Petersen F Bruseo C Wood AW Shivdasani RA Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex Cancer Cell 2004 5 1 91 102 10.1016/S1535-6108(03)00334-9 14749129 77. Fang L Zhu Q Neuenschwander M Specker E Wulf-Goldenberg A Weis WI von Kries JP Birchmeier W A Small-molecule antagonist of the β-Catenin/TCF4 interaction blocks the self-renewal of cancer stem cells and suppresses tumorigenesis Can Res 2016 76 4 891 901 10.1158/0008-5472.CAN-15-1519 78. Cha P-H Cho Y-H Lee S-K Lee J Jeong W-J Moon B-S Yun J-H Yang JS Choi S Yoon J Small-molecule binding of the axin RGS domain promotes β-catenin and Ras degradation Nat Chem Biol 2016 12 8 593 600 10.1038/nchembio.2103 27294323 79. Cha P-H Choi K-Y Simultaneous destabilization of β-catenin and Ras via targeting of the axin-RGS domain as a potential therapeutic strategy for colorectal cancer BMB Rep 2016 49 9 455 456 10.5483/BMBRep.2016.49.9.125 27470214 80. Ryu W-J Lee JD Park J-C Cha P-H Cho Y-H Kim JY Sohn JH Paik S Choi K-Y Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer Exp Mol Med 2020 52 5 832 842 10.1038/s12276-020-0440-y 32457491 81. Mathur R Sehgal L Braun FK Berkova Z Romaguerra J Wang M Rodriguez MA Fayad L Neelapu SS Samaniego F Targeting Wnt pathway in mantle cell lymphoma-initiating cells J Hematol Oncol 2015 8 63 10.1186/s13045-015-0161-1 26048374 82. Dandekar S Romanos-Sirakis E Pais F Bhatla T Jones C Bourgeois W Hunger SP Raetz EA Hermiston ML Dasgupta R Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia Br J Haematol 2014 167 1 87 99 10.1111/bjh.13011 24995804 83. Bilir B Kucuk O Moreno CS Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells J Transl Med 2013 11 280 10.1186/1479-5876-11-280 24188694 84. Ji L Qian W Gui L Ji Z Yin P Lin GN Wang Y Ma B Gao W-Q Blockade of β-Catenin-Induced CCL28 suppresses gastric cancer progression via inhibition of treg cell infiltration Can Res 2020 80 10 2004 2016 10.1158/0008-5472.CAN-19-3074 85. Catrow JL Zhang Y Zhang M Ji H Discovery of selective small-molecule inhibitors for the β-catenin/T-cell factor protein-protein interaction through the optimization of the acyl hydrazone moiety J Med Chem 2015 58 11 4678 4692 10.1021/acs.jmedchem.5b00223 25985283 86. Lee JH Faderl S Pagel JM Jung CW Yoon SS Pardanani AD Becker PS Lee H Choi J Lee K Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome Blood Adv 2020 4 9 2032 2043 10.1182/bloodadvances.2019000757 32396615 87. Kleszcz R Szymanska A Krajka-Kuzniak V Baer-Dubowska W Paluszczak J Inhibition of CBP/beta-catenin and porcupine attenuates Wnt signaling and induces apoptosis in head and neck carcinoma cells Cell Oncol (Dordr) 2019 42 4 505 520 10.1007/s13402-019-00440-4 31089983 88. Che M, Kweon SM, Teo JL, Yuan YC, Melstrom LG, Waldron RT, Lugea A, Urrutia RA, Pandol SJ, Lai KKY: Targeting the CBP/beta-Catenin Interaction to Suppress Activation of Cancer-Promoting Pancreatic Stellate Cells. Cancers (Basel) 2020, 12(6). 89. Xiang Q Wang C Zhang Y Xue X Song M Zhang C Li C Wu C Li K Hui X Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer Eur J Med Chem 2018 147 238 252 10.1016/j.ejmech.2018.01.087 29448139 90. Romero FA Murray J Lai KW Tsui V Albrecht BK An L Beresini MH de Leon BG Bronner SM Chan EW GNE-781, A highly advanced potent and selective bromodomain inhibitor of cyclic adenosine monophosphate response element binding protein, binding protein (CBP) J Med Chem 2017 60 22 9162 9183 10.1021/acs.jmedchem.7b00796 28892380 91. Evangelisti C Chiarini F Cappellini A Paganelli F Fini M Santi S Martelli AM Neri LM Evangelisti C Targeting Wnt/beta-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia J Cell Physiol 2020 235 6 5413 5428 10.1002/jcp.29429 31904116 92. Lenz HJ Kahn M Safely targeting cancer stem cells via selective catenin coactivator antagonism Cancer Sci 2014 105 9 1087 1092 10.1111/cas.12471 24975284 93. Osawa Y Oboki K Imamura J Kojika E Hayashi Y Hishima T Saibara T Shibasaki F Kohara M Kimura K Inhibition of cyclic adenosine monophosphate (cAMP)-response element-binding protein (CREB)-binding protein (CBP)/β-catenin reduces liver fibrosis in mice EBioMedicine 2015 2 11 1751 1758 10.1016/j.ebiom.2015.10.010 26870800 94. Wu G Cao L Zhu J Tan Z Tang M Li Z Hu Y Yu R Zhang S Song L Loss of RBMS3 confers platinum resistance in epithelial ovarian cancer via activation of miR-126-5p/beta-catenin/CBP signaling Clin Cancer Res 2019 25 3 1022 1035 10.1158/1078-0432.CCR-18-2554 30279231 95. Fendler A Bauer D Busch J Jung K Wulf-Goldenberg A Kunz S Song K Myszczyszyn A Elezkurtaj S Erguen B Inhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients Nature Commun 2020 11 1 929 10.1038/s41467-020-14700-7 32066735 96. Wiese M Hamdan FH Kubiak K Diederichs C Gielen GH Nussbaumer G Carcaboso AM Hulleman E Johnsen SA Kramm CM Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells Cell Death Dis 2020 11 8 673 10.1038/s41419-020-02800-7 32826850 97. Waaler J Machon O von Kries JP Wilson SR Lundenes E Wedlich D Gradl D Paulsen JE Machonova O Dembinski JL Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth Cancer Res 2011 71 1 197 205 10.1158/0008-5472.CAN-10-1282 21199802 98. Amado NG Predes D Fonseca BF Cerqueira DM Reis AH Dudenhoeffer AC Borges HL Mendes FA Abreu JG Isoquercitrin suppresses colon cancer cell growth in vitro by targeting the Wnt/β-catenin signaling pathway J Biol Chem 2014 289 51 35456 35467 10.1074/jbc.M114.621599 25359775 99. Bahrami A Amerizadeh F ShahidSales S Khazaei M Ghayour-Mobarhan M Sadeghnia HR Maftouh M Hassanian SM Avan A Therapeutic potential of targeting wnt/beta-catenin pathway in treatment of colorectal cancer: rational and progress J Cell Biochem 2017 118 8 1979 1983 10.1002/jcb.25903 28109136 100. Sarkar FH Li Y Wang Z Kong D Cellular signaling perturbation by natural products Cell Signal 2009 21 11 1541 1547 10.1016/j.cellsig.2009.03.009 19298854 101. Ashrafizadeh M Ahmadi Z Mohamamdinejad R Yaribeygi H Serban MC Orafai HM Sahebkar A Curcumin therapeutic modulation of the wnt signaling pathway Curr Pharm Biotechnol 2020 21 11 1006 1015 10.2174/1389201021666200305115101 32133961 102. Banerjee S Kong D Wang Z Bao B Hillman GG Sarkar FH Attenuation of multi-targeted proliferation-linked signaling by 3,3'-diindolylmethane (DIM): from bench to clinic Mutat Res 2011 728 1–2 47 66 10.1016/j.mrrev.2011.06.001 21703360 103. Yao JN Zhang XX Zhang YZ Li JH Zhao DY Gao B Zhou HN Gao SL Zhang LF Discovery and anticancer evaluation of a formononetin derivative against gastric cancer SGC7901 cells Invest New Drugs 2019 37 6 1300 1308 10.1007/s10637-019-00767-7 30929157 104. He L Lu N Dai Q Zhao Y Zhao L Wang H Li Z You Q Guo Q Wogonin induced G1 cell cycle arrest by regulating Wnt/β-catenin signaling pathway and inactivating CDK8 in human colorectal cancer carcinoma cells Toxicology 2013 312 36 47 10.1016/j.tox.2013.07.013 23907061 105. Yu S Wang Z Su Z Song J Zhou L Sun Q Liu S Li S Li Y Wang M Gigantol inhibits Wnt/β-catenin signaling and exhibits anticancer activity in breast cancer cells BMC complementary and alternative medicine 2018 18 1 59 10.1186/s12906-018-2108-x 29444668 106. Tang C Gong L Lvzi Xu, Qiu K, Zhang Z, Wan L: Echinacoside inhibits breast cancer cells by suppressing the Wnt/β-catenin signaling pathway Biochem Biophys Res Commun 2020 526 1 170 175 10.1016/j.bbrc.2020.03.050 32201078 107. Kavitha K Vidya Priyadarsini R Anitha P Ramalingam K Sakthivel R Purushothaman G Singh A Karunagaran D Nagini S Nimbolide, a neem limonoid abrogates canonical NF-κB and Wnt signaling to induce caspase-dependent apoptosis in human hepatocarcinoma (HepG2) cells Eur J Pharmacol 2012 681 6 14 10.1016/j.ejphar.2012.01.024 22327045 108. Amado N Predes D Fonseca B Cerqueira D Reis A Dudenhoeffer A Borges H Mendes F Abreu J Isoquercitrin suppresses colon cancer cell growth in vitro by targeting the Wnt/β-catenin signaling pathway J Biol Chem 2014 289 51 35456 35467 10.1074/jbc.M114.621599 25359775 109. Chinison J Aguilar JS Avalos A Huang Y Wang Z Cameron DJ Hao J Triptonide effectively inhibits Wnt/β-catenin signaling via c-terminal transactivation domain of β-catenin Sci Rep 2016 6 32779 10.1038/srep32779 27596363 110. Zhou R Yang Y Park S-Y Nguyen TT Seo Y-W Lee KH Lee JH Kim KK Hur J-S Kim H The lichen secondary metabolite atranorin suppresses lung cancer cell motility and tumorigenesis Sci Rep 2017 7 1 8136 10.1038/s41598-017-08225-1 28811522 111. Park S Gwak J Cho M Song T Won J Kim D Shin J Oh S Hexachlorophene inhibits Wnt/beta-catenin pathway by promoting Siah-mediated beta-catenin degradation Mol Pharmacol 2006 70 3 960 966 10.1124/mol.106.024729 16735606 112. Lu D Choi MY Yu J Castro JE Kipps TJ Carson DA Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells Proc Natl Acad Sci USA 2011 108 32 13253 13257 10.1073/pnas.1110431108 21788521 113. Tang Q-L Zhao Z-Q Li J-C Liang Y Yin J-Q Zou C-Y Xie X-B Zeng Y-X Shen J-N Kang T Salinomycin inhibits osteosarcoma by targeting its tumor stem cells Cancer Lett 2011 311 1 113 121 10.1016/j.canlet.2011.07.016 21835542 114. Sánchez-Tilló E Fanlo L Siles L Montes-Moreno S Moros A Chiva-Blanch G Estruch R Martinez A Colomer D Győrffy B The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma Cell Death Differ 2014 21 2 247 257 10.1038/cdd.2013.123 24013721 115. Mao J Fan S Ma W Fan P Wang B Zhang J Wang H Tang B Zhang Q Yu X Roles of Wnt/β-catenin signaling in the gastric cancer stem cells proliferation and salinomycin treatment Cell Death Dis 2014 5 e1039 10.1038/cddis.2013.515 24481453 116. Lu W Li Y Salinomycin suppresses LRP6 expression and inhibits both Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells J Cell Biochem 2014 115 10 1799 1807 10.1002/jcb.24850 24905570 117. Hung M Xu Z Chen Y Smith E Mao J Hsieh D Lin Y Yang C Jablons D You L Hematein, a casein kinase II inhibitor, inhibits lung cancer tumor growth in a murine xenograft model Int J Oncol 2013 43 5 1517 1522 10.3892/ijo.2013.2087 24008396 118. Yeh CT Wu AT Chang PM Chen KY Yang CN Yang SC Ho CC Chen CC Kuo YL Lee PY Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer Am J Respir Crit Care Med 2012 186 11 1180 1188 10.1164/rccm.201207-1180OC 23024022 119. Shaw V, Srivastava S, Srivastava SK: Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy. Semin Cancer Biol 2019. 120. Li B Yan J Phyu T Fan S Chung TH Mustafa N Lin B Wang L Eichhorn PJA Goh BC MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma Blood 2019 134 23 2046 2058 10.1182/blood.2019000381 31434700 121. Ren Y Tao J Jiang Z Guo D Tang J Pimozide suppresses colorectal cancer via inhibition of Wnt/β-catenin signaling pathway Life Sci 2018 209 267 273 10.1016/j.lfs.2018.08.027 30107167 122. Zhang R Li Y Tian D Liu Y Nian W Zou X Chen Q Zhou L Deng Z He B Ursolic acid inhibits proliferation and induces apoptosis by inactivating Wnt/β-catenin signaling in human osteosarcoma cells Int J Oncol 2016 49 5 1973 1982 10.3892/ijo.2016.3701 27665868 123. Li N Xi Y Tinsley H Gurpinar E Gary B Zhu B Li Y Chen X Keeton A Abadi A Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling Mol Cancer Ther 2013 12 9 1848 1859 10.1158/1535-7163.MCT-13-0048 23804703 124. Deng Y Su Q Mo J Fu X Zhang Y Lin E Celecoxib downregulates CD133 expression through inhibition of the Wnt signaling pathway in colon cancer cells Cancer Invest 2013 31 2 97 102 10.3109/07357907.2012.754458 23245395 125. Dunbar K, Valanciute A, Lima A, Vinuela P, Jamieson T, Rajasekaran V, Blackmur J, Ochocka-Fox A, Guazzelli A, Cammareri P et al: Aspirin rescues wnt-driven stem-like phenotype in human intestinal organoids and increases the wnt antagonist dickkopf-1. Cellular Mol Gastroenterol Hepatol 2020. 126. Yang Y Li X Wang T Guo Q Xi T Zheng L Emerging agents that target signaling pathways in cancer stem cells J Hematol Oncol 2020 13 1 60 10.1186/s13045-020-00901-6 32456660 127. Aulicino F, Pedone E, Sottile F, Lluis F, Marucci L, Cosma MP: Canonical wnt pathway controls mESC self-renewal through inhibition of spontaneous differentiation via beta-catenin/TCF/LEF functions. Stem Cell Rep 2020. 128. Takebe N Harris PJ Warren RQ Ivy SP Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways Nat Rev Clin Oncol 2011 8 2 97 106 10.1038/nrclinonc.2010.196 21151206 129. Takahashi-Yanaga F Kahn M Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 2010 16 12 3153 3162 10.1158/1078-0432.CCR-09-2943 20530697 130. Koury J Zhong L Hao J Targeting signaling pathways in cancer stem cells for cancer treatment Stem Cells Int 2017 2017 2925869 10.1155/2017/2925869 28356914 131. Liu D Du L Chen D Ye Z Duan H Tu T Feng J Yang Y Chen Q Yan X Reduced CD146 expression promotes tumorigenesis and cancer stemness in colorectal cancer through activating Wnt/β-catenin signaling Oncotarget 2016 7 26 40704 40718 10.18632/oncotarget.9930 27302922 132. Benoit YD Mitchell RR Risueno RM Orlando L Tanasijevic B Boyd AL Aslostovar L Salci KR Shapovalova Z Russell J Sam68 allows selective targeting of human cancer stem cells Cell Chem Biol 2017 24 7 833 844.e9 10.1016/j.chembiol.2017.05.026 28648376 133. Shooshtarizadeh P Helness A Vadnais C Brouwer N Beauchemin H Chen R Bagci H Staal FJT Coté J-F Möröy T Gfi1b regulates the level of Wnt/β-catenin signaling in hematopoietic stem cells and megakaryocytes Nat Commun 2019 10 1 1270 10.1038/s41467-019-09273-z 30894540 134. Kirstetter P Anderson K Porse BT Jacobsen SEW Nerlov C Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block Nat Immunol 2006 7 10 1048 1056 10.1038/ni1381 16951689 135. Zhao Z Lu P Zhang H Xu H Gao N Li M Liu C Nestin positively regulates the Wnt/beta-catenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells Breast Cancer Res 2014 16 4 408 10.1186/s13058-014-0408-8 25056574 136. Solzak JP Atale RV Hancock BA Sinn AL Pollok KE Jones DR Radovich M Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer Npj Breast Cancer 2017 3 17 10.1038/s41523-017-0016-8 28649657 137. Lin CK Bai MY Hu TM Wang YC Chao TK Weng SJ Huang RL Su PH Lai HC Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer Oncotarget 2016 7 8 8993 9006 10.18632/oncotarget.7113 26848771 138. Londono-Joshi AI Arend RC Aristizabal L Lu W Samant RS Metge BJ Hidalgo B Grizzle WE Conner M Forero-Torres A Effect of niclosamide on basal-like breast cancers Mol Cancer Ther 2014 13 4 800 811 10.1158/1535-7163.MCT-13-0555 24552774 139. Ye T Xiong Y Yan Y Xia Y Song X Liu L Li D Wang N Zhang L Zhu Y The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer model PLoS ONE 2014 9 1 e85887 10.1371/journal.pone.0085887 24416452 140. Burock S Daum S Keilholz U Neumann K Walther W Stein U Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial BMC Cancer 2018 18 1 297 10.1186/s12885-018-4197-9 29544454 141. Park SY Kim JY Choi JH Kim JH Lee CJ Singh P Sarkar S Baek JH Nam JS Inhibition of LEF1-mediated DCLK1 by niclosamide attenuates colorectal cancer stemness Clin Cancer Res 2019 25 4 1415 1429 10.1158/1078-0432.CCR-18-1232 30446587 142. Prabhu VV Lulla AR Madhukar NS Ralff MD Zhao D Kline CLB Van den Heuvel APJ Lev A Garnett MJ McDermott U Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors PLoS ONE 2017 12 8 e0180541 10.1371/journal.pone.0180541 28767654 143. Lev A Lulla AR Ross BC Ralff MD Makhov PB Dicker DT El-Deiry WS ONC201 targets AR and AR-V7 signaling, reduces PSA, and synergizes with everolimus in prostate cancer Mol Cancer Res 2018 16 5 754 766 10.1158/1541-7786.MCR-17-0614 29588330 144. Arrillaga-Romany I Odia Y Prabhu VV Tarapore RS Merdinger K Stogniew M Oster W Allen JE Mehta M Batchelor TT Biological activity of weekly ONC201 in adult recurrent glioblastoma patients Neuro Oncol 2020 22 1 94 102 10.1093/neuonc/noz164 31702782 145. Huang SM Mishina YM Liu S Cheung A Stegmeier F Michaud GA Charlat O Wiellette E Zhang Y Wiessner S Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling Nature 2009 461 7264 614 620 10.1038/nature08356 19759537 146. Roy S Roy S Kar M Chakraborty A Kumar A Delogu F Asthana S Hande MP Banerjee B Combined treatment with cisplatin and the tankyrase inhibitor XAV-939 increases cytotoxicity, abrogates cancer-stem-like cell phenotype and increases chemosensitivity of head-and-neck squamous-cell carcinoma cells Mutat Res 2019 846 503084 10.1016/j.mrgentox.2019.503084 31585633 147. Wu X Luo F Li J Zhong X Liu K Tankyrase 1 inhibitior XAV939 increases chemosensitivity in colon cancer cell lines via inhibition of the Wnt signaling pathway Int J Oncol 2016 48 4 1333 1340 10.3892/ijo.2016.3360 26820603 148. Martins-Neves SR Paiva-Oliveira DI Fontes-Ribeiro C Bovee J Cleton-Jansen AM Gomes CMF IWR-1, a tankyrase inhibitor, attenuates Wnt/beta-catenin signaling in cancer stem-like cells and inhibits in vivo the growth of a subcutaneous human osteosarcoma xenograft Cancer Lett 2018 414 1 15 10.1016/j.canlet.2017.11.004 29126913 149. Heng WS, Cheah SC: Chelerythrine chloride downregulates beta-catenin and inhibits stem cell properties of non-small cell lung carcinoma. Molecules 2020, 25(1). 150. Medvetz D Sun Y Li C Khabibullin D Balan M Parkhitko A Priolo C Asara JM Pal S Yu J High-throughput drug screen identifies chelerythrine as a selective inducer of death in a TSC2-null setting Mol Cancer Res 2015 13 1 50 62 10.1158/1541-7786.MCR-14-0440 25185584 151. Cheng Y Phoon YP Jin X Chong SY Ip JC Wong BW Lung ML Wnt-C59 arrests stemness and suppresses growth of nasopharyngeal carcinoma in mice by inhibiting the Wnt pathway in the tumor microenvironment Oncotarget 2015 6 16 14428 14439 10.18632/oncotarget.3982 25980501 152. Wu L He S He Y Wang X Lu L IC-2 Suppresses proliferation and induces apoptosis of bladder cancer cells via the wnt/beta-catenin pathway Med Sci Monit 2018 24 8074 8080 10.12659/MSM.910742 30415269 153. Kim M Cho H Yoon H Ahn Y Park E Jin Y Jang Y JIB-04, a small molecule histone demethylase inhibitor, selectively targets colorectal cancer stem cells by inhibiting the wnt/β-catenin signaling pathway Sci Rep 2018 8 1 6611 10.1038/s41598-018-24903-0 29700375 154. Gedaly R Galuppo R Daily MF Shah M Maynard E Chen C Zhang X Esser KA Cohen DA Evers BM Targeting the Wnt/beta-catenin signaling pathway in liver cancer stem cells and hepatocellular carcinoma cell lines with FH535 PLoS ONE 2014 9 6 e99272 10.1371/journal.pone.0099272 24940873 155. Razak S Afsar T Almajwal A Alam I Jahan S Growth inhibition and apoptosis in colorectal cancer cells induced by Vitamin D-Nanoemulsion (NVD): involvement of Wnt/β-catenin and other signal transduction pathways Cell Biosci 2019 9 15 10.1186/s13578-019-0277-z 30733856 156. Mackenzie G Ouyang N Xie G Vrankova K Huang L Sun Y Komninou D Kopelovich L Rigas B Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice Cancer Prevent Res (Philadelphia, Pa) 2011 4 7 1052 1060 10.1158/1940-6207.CAPR-11-0067 157. de Bessa Garcia SA Pavanelli AC Cruz E Melo N, Nagai MA: Prostate apoptosis response 4 (PAR4) expression modulates WNT signaling pathways in MCF7 breast cancer cells: A possible mechanism underlying PAR4-mediated docetaxel chemosensitivity Int J Mol Med 2017 39 4 809 818 10.3892/ijmm.2017.2900 28259909 158. Xu L Zhang L Hu C Liang S Fei X Yan N Zhang Y Zhang F WNT pathway inhibitor pyrvinium pamoate inhibits the self-renewal and metastasis of breast cancer stem cells Int J Oncol 2016 48 3 1175 1186 10.3892/ijo.2016.3337 26781188 159. Gwak J Hwang SG Park H-S Choi SR Park S-H Kim H Ha N-C Bae SJ Han J-K Kim D-E Small molecule-based disruption of the Axin/β-catenin protein complex regulates mesenchymal stem cell differentiation Cell Res 2012 22 1 237 247 10.1038/cr.2011.127 21826110 160. Cho YH Ro EJ Yoon JS Mizutani T Kang DW Park JC Il Kim T Clevers H Choi KY 5-FU promotes stemness of colorectal cancer via p53-mediated WNT/beta-catenin pathway activation Nat Commun 2020 11 1 5321 10.1038/s41467-020-19173-2 33087710 161. Prieur A Cappellini M Habif G Lefranc MP Mazard T Morency E Pascussi JM Flaceliere M Cahuzac N Vire B Targeting the wnt pathway and cancer stem cells with anti-progastrin humanized antibodies as a potential treatment for K-Ras-mutated colorectal cancer Clin Cancer Res 2017 23 17 5267 5280 10.1158/1078-0432.CCR-17-0533 28600477 162. Cui C Zhou X Zhang W Qu Y Ke X Is beta-catenin a druggable target for cancer therapy? Trends Biochem Sci 2018 43 8 623 634 10.1016/j.tibs.2018.06.003 30056837 163. Pai SG Carneiro BA Mota JM Costa R Leite CA Barroso-Sousa R Kaplan JB Chae YK Giles FJ Wnt/beta-catenin pathway: modulating anticancer immune response J Hematol Oncol 2017 10 1 101 10.1186/s13045-017-0471-6 28476164 164. Kahn M Can we safely target the WNT pathway? Nat Rev Drug Discov 2014 13 7 513 532 10.1038/nrd4233 24981364 165. Lamture G Crooks PA Borrelli MJ Actinomycin-D and dimethylamino-parthenolide synergism in treating human pancreatic cancer cells Drug Dev Res 2018 79 6 287 294 10.1002/ddr.21441 30295945